Ambrisentan + Placebo + Sildenafil + Tadalafil
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Apr 1, 2008 → Jul 1, 2011
NCT ID
NCT00617305About Ambrisentan + Placebo + Sildenafil + Tadalafil
Ambrisentan + Placebo + Sildenafil + Tadalafil is a approved stage product being developed by Gilead Sciences for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00617305. Target conditions include Pulmonary Arterial Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Arterial Hypertension were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00617305 | Approved | Completed |
Competing Products
20 competing products in Pulmonary Arterial Hypertension